Abstract
Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for the prevention and treatment of thromboembolic diseases. In comparison with current treatment standards for venous thromboembolism (VTE) prophylaxis, apixaban has shown decreased rates of clinically significant bleeding with mixed results in terms of non-inferiority for VTE events. Secondary treatment of VTE with apixaban is currently in phase III clinical study after earlier trials showed comparable safety and efficacy outcomes. The APPRAISE-1 trial, a phase II investigation of apixaban versus placebo following acute coronary syndrome showed a higher risk of clinically significant bleeding in addition to a trend toward decreased ischemic events. A large, international phase III clinical study (APPRAISE-2) of apixaban following acute coronary syndrome is currently underway. Large, phase III studies testing apixaban for the prevention of vascular events in subjects with non-valvular atrial fibrillation are also ongoing.
References
Jul 2, 1985·Biochemistry·S YoshitakeK Kurachi
Sep 18, 2007·Journal of Thrombosis and Haemostasis : JTH·M R LassenD Deitchman
Oct 5, 2007·Journal of Medicinal Chemistry·Donald J P PintoPatrick Y S Lam
Dec 20, 2007·Journal of Thrombosis and Haemostasis : JTH·B I ErikssonUNKNOWN Fixit Study Group
Mar 5, 2008·Journal of Thrombosis and Haemostasis : JTH·P C WongR M Knabb
Jun 11, 2008·Journal of Thrombosis and Haemostasis : JTH·UNKNOWN Botticelli Investigators, Writing CommitteA Segers
Jul 24, 2008·Chest·William H GeertsClifford W Colwell
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Dec 17, 2008·Clinical Pharmacokinetics·Bengt I ErikssonJeffrey I Weitz
Apr 8, 2009·Thrombosis and Haemostasis·Xiaosui JiangPancras C Wong
May 28, 2009·Circulation·UNKNOWN APPRAISE Steering Committee and InvestigatorsLars Wallentin
Aug 7, 2009·The New England Journal of Medicine·Michael Rud LassenRonald J Portman
Mar 9, 2010·Lancet·Michael Rud LassenUNKNOWN ADVANCE-2 investigators
Apr 5, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Kan HeScott J Grossman
Citations
Feb 24, 2010·Journal des maladies vasculaires·A Godier, C-M Samama
Apr 3, 2012·Journal of Thrombosis and Thrombolysis·Davide ImbertiRoberto Manfredini
Aug 7, 2012·Journal of Thrombosis and Thrombolysis·Kimberly L CarterKenneth M Shermock
Nov 9, 2010·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·David Stegner, Bernhard Nieswandt
Mar 8, 2013·Hospital Practice·Taki Galanis, Geno J Merli
May 15, 2013·Expert Opinion on Drug Safety·Flavio de Souza BritoJohn H Alexander
Jan 17, 2012·The American Journal of the Medical Sciences·Harsh GolwalaMazen S Abu-Fadel
Apr 3, 2013·Chest·Christopher S KingLisa K Moores
Aug 7, 2012·Neurología : publicación oficial de la Sociedad Española de Neurología·G Zapata WainbergJ Vivancos Mora
Apr 27, 2011·Transfusion·Arthur W BraceyPaul M Allison
Sep 29, 2011·Pharmacotherapy·Estella M DavisJennifer A Campbell
Jul 22, 2010·Cardiovascular Therapeutics·Luke R E Bereznicki, Gregory M Peterson
Sep 18, 2016·Hematology/oncology Clinics of North America·Nicoletta Riva, Walter Ageno
Oct 15, 2011·Journal of Medicinal Chemistry·Fukushi HirayamaShin-ichi Tsukamoto
May 12, 2011·International Journal of Stroke : Official Journal of the International Stroke Society·Luca MasottiDomenico Prisco
Jan 15, 2014·Hospital Pharmacy·Dennis J CadaDanial E Baker
Mar 13, 2012·Clinical Medicine Insights. Cardiology·Yousif Ahmad, Gregory Y H Lip
May 21, 2014·Cardiovascular Drugs and Therapy·A JalotaJ Halperin
Feb 15, 2011·American Journal of Therapeutics·Suraj ChandrasekarRohit Arora
Jul 27, 2021·Ophthalmic Surgery, Lasers & Imaging Retina·Matthew R StarrAllen Chiang
Oct 27, 2017·Journal of Medicinal Chemistry·Peter M Fischer
Nov 30, 2021·Journal of the American Chemical Society·Wowa StroekMartin Albrecht